Britain to allow '3-parent' IVF to prevent congenital disease

Breakthrough treatment would allow genes from a donor female egg to be spliced into an embryo to prevent congenital diseases

PUBLISHED : Saturday, 29 June, 2013, 12:00am
UPDATED : Saturday, 29 June, 2013, 5:07am

Britain is planning to become the first country in the world to offer controversial "three-parent" fertility treatments to families who want to avoid passing on incurable diseases to their children.

The methods, at the research stage in laboratories in Britain and the United States, would for the first time involve implanting into women embryos with genetic material from three "parents", raising big ethical issues.

The techniques involve intervening in the fertilisation process to remove faulty mitochondrial DNA, which can cause inherited conditions such as fatal heart problems, liver failure, brain disorders, blindness and muscular dystrophy.

They are designed to help families with mitochondrial diseases - incurable conditions passed down the maternal line that affect about one in 6,500 children worldwide. Mitochondria act as tiny energy-generating batteries inside cells.

The controversial potential treatment is known as three-parent in vitro fertilisation (IVF) because the offspring would have genes from a mother, a father and from a female donor.

After a national public consultation showed Britons broadly favour the idea, the government's chief physician said yesterday it should be allowed to go ahead under strict regulation.

"Scientists have developed ground-breaking new procedures which could stop these diseases being passed on, bringing hope to many families seeking to prevent their children inheriting them," chief medical officer Sally Davies said.

"It's only right that we look to introduce this life-saving treatment as soon as we can."

Davies said the government's health department was drafting regulations to cover the new treatments and planned to publish them later this year. The move would make Britain the first country in the world to give patients the option of using so-called mitochondrial DNA transfer to avoid passing the diseases on to their children.

Scientists are researching several three-parent IVF techniques.

One being developed at Britain's Newcastle University, known as pronuclear transfer, swaps DNA between two fertilised human eggs. Another, called maternal spindle transfer, swaps material between the mother's egg and a donor egg before fertilisation.

A British medical ethics panel which reviewed the potential treatments for mitochondrial diseases decided last year they were ethical and should go ahead as long as research shows they are likely to be safe and effective.

Because Britain is in the vanguard of this research, ethical concerns, political decisions and scientific advances there are closely watched around the world, particularly in the US, where scientists are also working on DNA swap techniques.

Some anti-abortion campaigners have criticised the scientific research, saying that creating embryonic children in a lab abuses them by subjecting them to unnatural processes.

Critics also worry that modifying embryos to avoid disease could be the first step towards "designer babies", whose genetic make-up could be modified as embryos to ensure certain traits such as height or hair colour.

Human Genetics Alert director David King said "the techniques are unnecessary and their use is ethically unsound" and criticised the government for failing to conduct a more comprehensive public consultation.

"They cross the ethical line that has been agreed by governments around the world that we should not genetically alter human beings," he said.

Asked whether she was "comfortable" with taking such a major step along the way to allowing human genetic modification, Davies said she had debated and considered the ethical implications with many experts over many years and had come to the conclusion the techniques should be allowed.

Any final decision on putting the regulations in place to allow the new treatments to be offered will be subject to a vote in parliament, but Davies said she hoped the first patients may be able to get the new treatments within the next two years.